460 related articles for article (PubMed ID: 28902084)
21. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
22. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
Brusamolino E; Lunghi F; Orlandi E; Astori C; Passamonti F; Baraté C; Pagnucco G; Baio A; Franchini P; Lazzarino M; Bernasconi C
Haematologica; 2000 Oct; 85(10):1032-9. PubMed ID: 11025593
[TBL] [Abstract][Full Text] [Related]
23. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group.
Fryer CJ; Hutchinson RJ; Krailo M; Collins RD; Constine LS; Hays DM; Heller RM; Davis PC; Nachman J; O'Brien RT
J Clin Oncol; 1990 Dec; 8(12):1971-80. PubMed ID: 1700080
[TBL] [Abstract][Full Text] [Related]
25. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
Bhethanabhotla S; Jain S; Kapoor G; Mahajan A; Chopra A; Vishnubhatla S; Bakhshi S
Leuk Lymphoma; 2017 Jul; 58(7):1617-1623. PubMed ID: 27919174
[TBL] [Abstract][Full Text] [Related]
26. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
27. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
28. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
Anselmo AP; Cavalieri E; Osti FM; Cantonetti M; De Sanctis V; Alfo M; Amadori S; Enrici RM
Anticancer Res; 2004; 24(6):4045-50. PubMed ID: 15736450
[TBL] [Abstract][Full Text] [Related]
29. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
30. Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India.
Parambil BC; Narula G; Prasad M; Shah S; Shet T; Shridhar E; Khanna N; Laskar S; Gujral S; Sankaran H; Banavali S
Pediatr Blood Cancer; 2020 Feb; 67(2):e28058. PubMed ID: 31724304
[TBL] [Abstract][Full Text] [Related]
31. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
32. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
Hay AE; Klimm B; Chen BE; Goergen H; Shepherd LE; Fuchs M; Gospodarowicz MK; Borchmann P; Connors JM; Markova J; Crump M; Lohri A; Winter JN; Dörken B; Pearcey RG; Diehl V; Horning SJ; Eich HT; Engert A; Meyer RM;
Ann Oncol; 2013 Dec; 24(12):3065-9. PubMed ID: 24121121
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
Ogura M; Itoh K; Kinoshita T; Fukuda H; Takenaka T; Ohtsu T; Kagami Y; Tobinai K; Okamoto M; Asaoku H; Sasaki T; Mikuni C; Hirano M; Chou T; Ohnishi K; Ohno H; Nasu K; Okabe K; Ikeda S; Nakamura S; Hotta T; Shimoyama M
Int J Hematol; 2010 Dec; 92(5):713-24. PubMed ID: 21076995
[TBL] [Abstract][Full Text] [Related]
34. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P;
Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123
[TBL] [Abstract][Full Text] [Related]
35. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ; Lowry L; Horwich A; Jack A; Mead B; Hancock BW; Smith P; Qian W; Patrick P; Popova B; Pettitt A; Cunningham D; Pettengell R; Sweetenham J; Linch D; Johnson PW
J Clin Oncol; 2009 Nov; 27(32):5390-6. PubMed ID: 19738111
[TBL] [Abstract][Full Text] [Related]
36. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
[TBL] [Abstract][Full Text] [Related]
37. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
[TBL] [Abstract][Full Text] [Related]
38. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
39. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
40. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
